PROKIDNEY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.12 USD | -21.77% |
|
-22.06% | +19.10% |
| Mar. 25 | ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations | CI |
| Mar. 22 | ProKidney Posts Wider 2023 Loss | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 136M |
|---|---|---|---|---|---|
| Net income 2024 * | -176M | Net income 2025 * | -40M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 152M | Net cash position 2025 * | 295M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.65
x | P/E ratio 2025 * |
-5.44
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 day | -21.77% | ||
| 1 week | -22.06% | ||
| Current month | +29.27% | ||
| 1 month | +29.27% | ||
| 3 months | +43.24% | ||
| 6 months | +40.86% | ||
| Current year | +19.10% |
1 week
2.06
3.02
1 month
1.413.37
Current year
1.183.37
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 23-07-16 |
James Coulston
DFI | Director of Finance/CFO | 48 | 21-12-31 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 21-12-31 |
Brian Pereira
BRD | Director/Board Member | 65 | 21-12-31 |
John Maraganore
BRD | Director/Board Member | 60 | 22-08-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 2.3 | +8.49% | 778,586 |
| 24-04-26 | 2.12 | -21.77% | 1,533,641 |
| 24-04-25 | 2.71 | 0.00% | 495,834 |
| 24-04-24 | 2.71 | +7.11% | 541,639 |
| 24-04-23 | 2.53 | -6.99% | 1,152,575 |
End-of-day quote Nasdaq, April 25, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.3
USD
Average target price
4.2
USD
Spread / Average Target
+82.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.10% | 136M | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
- Stock Market
- Equities
- PROK Stock
